Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
Study sponsor: Ocular Therapeutix, Inc. · OCUL
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-01-08Estimated
Enrollment · participants825Estimated
Source updated2025-06-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.